MX2022004049A - Tratamiento basado en biomarcadores de la glomeruloesclerosis focal y segmentaria y de la enfermedad renal diabetica. - Google Patents
Tratamiento basado en biomarcadores de la glomeruloesclerosis focal y segmentaria y de la enfermedad renal diabetica.Info
- Publication number
- MX2022004049A MX2022004049A MX2022004049A MX2022004049A MX2022004049A MX 2022004049 A MX2022004049 A MX 2022004049A MX 2022004049 A MX2022004049 A MX 2022004049A MX 2022004049 A MX2022004049 A MX 2022004049A MX 2022004049 A MX2022004049 A MX 2022004049A
- Authority
- MX
- Mexico
- Prior art keywords
- kidney disease
- biomarkers
- focal
- treatment based
- segmental glomerulosclerosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Radiation-Therapy Devices (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962910758P | 2019-10-04 | 2019-10-04 | |
| PCT/US2020/054282 WO2021067946A1 (en) | 2019-10-04 | 2020-10-05 | Biomarker-based treatment of focal segmental glomerulosclerosis and diabetic kidney disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022004049A true MX2022004049A (es) | 2022-07-11 |
Family
ID=75337492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022004049A MX2022004049A (es) | 2019-10-04 | 2020-10-05 | Tratamiento basado en biomarcadores de la glomeruloesclerosis focal y segmentaria y de la enfermedad renal diabetica. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240091303A1 (https=) |
| EP (1) | EP4037680A4 (https=) |
| JP (2) | JP2022551580A (https=) |
| KR (1) | KR20220079907A (https=) |
| AU (1) | AU2020357178A1 (https=) |
| CA (1) | CA3156814A1 (https=) |
| IL (1) | IL291903A (https=) |
| MX (1) | MX2022004049A (https=) |
| PH (1) | PH12022550818A1 (https=) |
| WO (1) | WO2021067946A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA71645A (fr) * | 2018-09-18 | 2025-05-30 | Goldfinch Bio, Inc. | Pyridazinones et leurs procédés d'utilisation |
| CN115927202A (zh) * | 2023-01-10 | 2023-04-07 | 北京爱思益普生物科技股份有限公司 | 一种trpc5突变细胞株及其构建方法和应用 |
| WO2024164818A1 (zh) * | 2023-02-08 | 2024-08-15 | 中国科学院上海药物研究所 | 黄嘌呤类化合物及其用途 |
| CN116919965B (zh) * | 2023-05-24 | 2024-05-17 | 徐州医科大学 | 一种trpml1特异性小分子抑制剂ml-si3的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8633233B2 (en) * | 2008-08-06 | 2014-01-21 | Hydra Biosciences, Inc. | Methods and compositions for treating anxiety |
| JP5795311B2 (ja) * | 2009-07-15 | 2015-10-14 | ネステク ソシエテ アノニム | 抗体ベースのアレイを使用する胃癌療法のための薬物選択 |
| US20110135574A1 (en) * | 2009-11-16 | 2011-06-09 | Anna Greka | Methods of treating kidney disease |
| JO3470B1 (ar) * | 2012-10-08 | 2020-07-05 | Merck Sharp & Dohme | مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv |
| DK3652176T3 (da) * | 2017-07-11 | 2022-01-17 | Boehringer Ingelheim Int | Substituerede xanthinderivater |
| WO2019028309A1 (en) * | 2017-08-04 | 2019-02-07 | Goldfinch Bio, Inc. | AZAINDOLES AND THEIR METHODS OF USE |
| WO2019028308A1 (en) * | 2017-08-04 | 2019-02-07 | Goldfinch Bio, Inc. | BENZIMIDAZOLES AND AZA-BENZIMIDAZOLES AND METHODS OF USE |
| US11370769B2 (en) * | 2017-09-07 | 2022-06-28 | Board Of Regents Of The University Of Nebraska | TRPC5 inhibitors and methods of using same |
| EP3684364A4 (en) * | 2017-09-18 | 2021-06-02 | Goldfinch Bio, Inc. | PYRIDAZINONE AND METHOD OF USE THEREOF |
| CA3093084A1 (en) * | 2018-03-05 | 2019-09-12 | Goldfinch Bio, Inc. | Imidazodiazepinediones and methods of use thereof |
| MA71645A (fr) * | 2018-09-18 | 2025-05-30 | Goldfinch Bio, Inc. | Pyridazinones et leurs procédés d'utilisation |
| WO2020206623A1 (en) * | 2019-04-10 | 2020-10-15 | Goldfinch Bio, Inc. | Crystal forms |
-
2020
- 2020-10-05 JP JP2022520229A patent/JP2022551580A/ja active Pending
- 2020-10-05 IL IL291903A patent/IL291903A/en unknown
- 2020-10-05 EP EP20871404.8A patent/EP4037680A4/en active Pending
- 2020-10-05 AU AU2020357178A patent/AU2020357178A1/en active Pending
- 2020-10-05 WO PCT/US2020/054282 patent/WO2021067946A1/en not_active Ceased
- 2020-10-05 MX MX2022004049A patent/MX2022004049A/es unknown
- 2020-10-05 KR KR1020227015035A patent/KR20220079907A/ko active Pending
- 2020-10-05 US US17/766,492 patent/US20240091303A1/en active Pending
- 2020-10-05 CA CA3156814A patent/CA3156814A1/en active Pending
- 2020-10-05 PH PH1/2022/550818A patent/PH12022550818A1/en unknown
-
2025
- 2025-09-11 JP JP2025150734A patent/JP2025183335A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3156814A1 (en) | 2021-04-08 |
| KR20220079907A (ko) | 2022-06-14 |
| IL291903A (en) | 2022-06-01 |
| JP2025183335A (ja) | 2025-12-16 |
| PH12022550818A1 (en) | 2023-09-11 |
| JP2022551580A (ja) | 2022-12-12 |
| EP4037680A4 (en) | 2023-10-04 |
| EP4037680A1 (en) | 2022-08-10 |
| WO2021067946A1 (en) | 2021-04-08 |
| AU2020357178A1 (en) | 2022-05-12 |
| US20240091303A1 (en) | 2024-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022004049A (es) | Tratamiento basado en biomarcadores de la glomeruloesclerosis focal y segmentaria y de la enfermedad renal diabetica. | |
| MX2021007152A (es) | Inhibidores de apol1 y sus metodos de uso. | |
| MX2020009991A (es) | Metodos basados en anticuerpos para detectar y tratar la enfermedad de alzheimer. | |
| CY1123833T1 (el) | Μεθοδοι προληψης καρδιαγγειακων συμβαντων σε δυσλιπιδαιμικους πληθυσμους υπολειπομενου κινδυνου | |
| EA202192130A1 (ru) | Специфичные к ltbp-комплексу ингибиторы tgf и их применение | |
| MA55145A (fr) | <sup2/>? <sub2/>?g12c? ?polythérapie comprenant un inhibiteur de kraset un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers | |
| EA202192606A1 (ru) | Антитела к пироглутамат--амилоиду и их применение | |
| EA200901313A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| EA200600078A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
| MX2021011316A (es) | Piridazinonas y metodos de uso de estas. | |
| EA200702053A1 (ru) | Антитела против cd38 для лечения множественной миеломы | |
| EA201792191A1 (ru) | Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли | |
| EA201301180A1 (ru) | Основанная на bcma стратификация и терапия пациентов, страдающих множественной миеломой | |
| EA201391587A1 (ru) | Комбинированная терапия на основе hsp90 | |
| EP3938138A4 (en) | LASER PROCESSING DEVICE, METHOD OF OPERATING THEREOF, AND METHOD OF PROCESSING WORKPIECES USING THEREOF | |
| EA202191058A1 (ru) | Антитела против муцина-16 и способы их применения | |
| MX2022003820A (es) | Metodos de tratamiento para modificar la hermodinamica. | |
| AR113850A1 (es) | Antagonistas de ildr2 y combinaciones de los mismos | |
| EA202193038A1 (ru) | Антитела против sema3a и их применения для лечения заболеваний глаз | |
| BRPI0517790A (pt) | métodos e composições fluoradas para tratar doenças relacionadas à amilóide | |
| EA202192961A1 (ru) | Ребамипид для применения в профилактике и/или лечении синуклеинопатий | |
| MX2018006250A (es) | Biomarcador de enfermedad poliquistica renal y usos del mismo. | |
| CL2022000752A1 (es) | Molécula de unión específica para lif y uso de la misma | |
| BR112022006184A2 (pt) | Tratamento baseado em biomarcadores da glomeruloesclerose segmentar focal e doença renal diabética | |
| MX2022007116A (es) | Anticuerpo anti-c5 para el tratamiento del trastorno del espectro de la neuromielitis optica. |